BCRX
BioCryst Pharmaceuticals, Inc.
BCRX has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over BCRX overall, supported by stronger fundamentals and stronger modeled upside.
BCRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Strong | |
| Strong |
BCRX's revenue, cash flow and balance sheet are currently healthy, but its profitability is weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BCRX PE Valuation
BCRX has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
BCRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for BCRX, with profitability improving. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
BCRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.66 | — |
| Q3 2026 | -$1.41 | -$1.36 |
| Q2 2026 | -$1.49 | -$1.31 |
| Q1 2026 | -$1.77 | -$1.51 |
| Q4 2025 | $1.21 | +$1.64 |
| Q3 2025 | -$0.05 | +$0.56 |
| Q2 2025 | -$0.18 | +$0.55 |
| Q1 2025 | -$0.26 | +$0.81 |
| Q4 2024 | -$0.43 | +$0.75 |
BCRX lost $1.41 per share over the past year, a bigger loss than the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over BCRX on earnings quality, reporting a profit while its opponent remains loss making.
BCRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $180.3M | +13% |
| Q2 2026 | $218.3M | +34% |
| Q1 2026 | $156.4M | +7.5% |
| Q4 2025 | $406.6M | +209% |
| Q3 2025 | $159.4M | +36% |
| Q2 2025 | $163.4M | +49% |
| Q1 2025 | $145.5M | +57% |
| Q4 2024 | $131.5M | +41% |
BCRX's revenue has grown year over year for 23 quarters in a row: $180M last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | +11 points |
| Q2 2026 | 45% | +27 points |
| Q1 2026 | -449% | -463 points |
| Q4 2025 | 64% | +68 points |
| Q3 2025 | 19% | +12 points |
| Q2 2025 | 18% | +10 points |
| Q1 2025 | 15% | +30 points |
| Q4 2024 | -3.4% | +42 points |
BCRX has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BCRX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
BCRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $32.8M | -19% |
| Q2 2026 | $104.1M | +153% |
| Q1 2026 | -$62.2M | -$34.5M |
| Q4 2025 | $291.2M | +$297M |
| Q3 2025 | $40.3M | +392% |
| Q2 2025 | $41.1M | +$42.6M |
| Q1 2025 | -$27.7M | +$26.3M |
| Q4 2024 | -$5.9M | +$3.6M |
BCRX has burned cash in most quarters: $366M over the past year, about eight times what it generated the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
BCRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.5M shares |
| 1 year | +22% | +47.7M shares |
| 3 years | +41% | +78M shares |
| 5 years | +51% | +90.3M shares |
| Available history | +74% | +113M shares |
BCRX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BCRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | 1.4x | Healthy |
| Q2 2025 | 2.8x | Moderate |
| Q1 2025 | 6.1x | High |
BCRX has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
BCRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.7 | Neutral |
| Stochastic | 16.2 | Oversold |
BCRX's weekly RSI is 43 (neutral) and its Stochastic is 16 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BCRX PE vs Healthcare Sector
BCRX has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BCRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.07 | 4.8% below |
| 20 week MA | $8.89 | 14% below |
| 50 week MA | $8.50 | 9.6% below |
| 100 week MA | $8.38 | 8.4% below |
| 200 week MA | $7.71 | 0.4% below |
BCRX is in a downtrend: it's below all five of its weekly moving averages, and 0.4% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over BCRX on trend strength, trading above more of its moving averages.
BCRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.12 | $7.28 | +133% |
| 2021 | $7.28 | $13.9 | +91% |
| 2022 | $13.9 | $11.5 | -18% |
| 2023 | $11.5 | $5.99 | -48% |
| 2024 | $5.99 | $7.71 | +29% |
| 2025 | $7.71 | $7.63 | -1% |
| 2026 YTD | $7.63 | $7.68 | +0.7% |
BCRX's yearly returns have swung widely, from +133% in 2020 to −48% in 2023. It's up 0.7% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BCRX on returns for 2026, with the stronger performance.